HD Insights Volume 15

HD Insights: Volume 15

HD Insights Volume 15 (PDF)

October 31st, 2016 Heather Hare To read a non-PDF version of HD Insights Vol. 15, click here.

Finding balance in HD: The role of PIAS1 in protein homeostasis

October 31st, 2016 Heather Hare By: Joseph Ochaba, PhD There are currently no medications or treatments to alter the devastating course of HD. Although some medications to ameliorate HD symptoms exist, they are often of limited effectiveness;1 therefore, there is a great need to develop treatments and discover targets to effectively alter the course of HD. As in many other
+ Read More

Meet the Company: WAVE Life Sciences

October 31st, 2016 Heather Hare VITAL SIGNSName: WAVE Life SciencesStock symbol: WVEShare price as of 10/9/16: $30.27Market capitalization: $574 millionU.S. Headquarters: Cambridge, MA Precision Medicine for HD WAVE Life Sciences, a preclinical biopharmaceutical company publicly traded since 2015, utilizes their proprietary platform to synthesize stereopure nucleic acid therapies for currently untreatable genetic diseases. HD Insights spoke with Brenda Jeglinski, Director
+ Read More

Meet the Compounds: WVE-120101 and WVE-120102

October 31st, 2016 Heather Hare By: Meredith A. Achey, BMManufacturer: WAVE Life SciencesMolecular formula: Stereopure antisense oligonucleotide (ASO) targeting single nucleotide polymorphisms (SNPs).Mechanism of action: WVE-120101 and WVE-120102 act by selectively binding mHTT mRNA, thereby selectively inhibiting production of mHTT. WAVE Life Sciences has developed a strategy to synthesize stereopure nucleotide-based therapies that may improve their efficacy and safety.1 Nucleotide-based
+ Read More

Highlights from the Journal of Huntington’s Disease

October 31st, 2016 Heather Hare Induced pluripotent stem cells in HD researchBy: Kimberly Kegel-Gleason, PhDOriginal article: Tousley A, Kegel-Gleason KB. Induced Pluripotent Stem Cells in Huntington’s Disease Research: Progress and Opportunity. J Huntingtons Dis. 2016 Jun 28;5(2):99-131. doi: 10.3233/JHD-160199. Although many cell types are affected in HD, the impact of the disease on CNS neurons is remarkable. Neurons of the
+ Read More

Career Opportunity: Vice President, Global Specialty Development, NDD, Teva

October 31st, 2016 Heather Hare Vice President, Global Specialty Development, NDD The Role The Vice President, Global Clinical Development, NDD will report directly to the Vice President, Global Head, NDD/MDS & Clinical Research Innovation within the global R&D function, overseeing the clinical development of Huntington’s Disease. This is a critical role within the company, having a significant impact in defining
+ Read More

Career Opportunity: Director/Sr. Director Global Specialty Development, Neurodegenerative Diseases, Teva

October 31st, 2016 Heather Hare Director/Sr. Director Global Specialty Development, Neurodegenerative Diseases The Role The Director/Sr. Director is responsible for the development, execution and management of multiple clinical programs worldwide across all phases of clinical research in the areas of Neurodegenerative Diseases (NDD). Reporting to the VP, Global Head of NDD Clinical Development, the Director/Sr. Director will oversee clinical study
+ Read More

Meet the Next Generation

October 31st, 2016 Heather Hare The global HD research community continues to grow and welcome a new, diverse generation of investigators. As we did in 2015, HD Insights interviewed next-generation HD researchers who have been invited by the HSG to attend the 2016 HSG Annual Meeting. We bring you their backgrounds, their current work, and their vision for the future
+ Read More

Editor’s Letter

October 31st, 2016 Heather Hare Welcome to the 15th edition of HD Insights, released at the 2016 Huntington Study Group (HSG) Annual Meeting in Nashville, TN. We are proud to be celebrating five years of pursuing our mission to promote, disseminate, and facilitate HD research with content that is valuable and informative to the global community of HD researchers. This
+ Read More